Upon completion of this activity, participants should be able to:

• Describe the evidence behind current practices related to liver transplantation for patients with alcohol use disorder and alcohol-associated liver         disease.
• Review post-transplant outcomes in patients with alcohol use disorder and alcohol-associated liver disease.
• Identify approaches to providing alcohol use disorder treatment for patients with alcohol-associated liver disease across the pre- and post-transplant continuum

This webinar is hosted by the American Association for the Study of Liver Diseases (AASLD). AASLD is a PCSS-MAUD partner.

Funding for this initiative was made possible by cooperative
agreement no. 1H79TI086771-01 from SAMHSA. The views expressed in written
conference materials or publications and by speakers and moderators do not necessarily
reflect the official policies of the Department of Health and Human Services; nor does
mention of trade names, commercial practices, or organizations imply endorsement by
the U.S. Government.

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes.

All relevant conflicts pertaining to this activity have been mitigated. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Lamia Haque, MD, MPH
Nothing to Disclose

Brian P. Lee, MD
Scientific Consultant:  GlaxoSmithKline, NovoNordisk, HepaTx, Ipsen, CymaBay, AltImmune
Grant/Research Suppport: Simens Healthineers

Jessica Mellinger, MD
Scientific Consulting: GlaxoSmithKline

Juan Pablo Arab, MD, FRCPC
Nothing to Disclose

Gerald Scott Winder, MD, MSc
Scientific Consultant: GlaxoSmithKline

Staff:

Laura Shelters, MS, Ed.
Nothing to Disclose

Sally Cook, CMP, CHCP
Nothing to Disclose